Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 35

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 35
---
40,000 for her role as a director, payable in quarterly installments. Consistent with the terms of the non-employee director compensation policy, following February 6, 2025, when the Stelzer Agreement terminated in connection with our initial public offering, Ms. Stelzer receives $40,000 for her role as a director and $16,000 for her role as the chair of the audit committee, payable in quarterly installments, as well as reimbursement for reasonable travel expenses incurred by Ms. Stelzer for her attendance at meetings of our board of directors.

Marcella Ruddy

On December 18, 2024, we entered into a board of directors agreement with Marcella Ruddy (the “Ruddy Agreement”) pursuant to which Dr. Ruddy began serving as a director and member of the nominating and corporate governance committee, effective as of January 6, 2025. Pursuant to the Ruddy Agreement, on February 6, 2025, the date on which the registration statement of our initial public offering was declared effective by the SEC, Ms. Ruddy received an initial equity grant under the non-employee director compensation policy. Following February 6, 2025, consistent with the terms of the non-employee director compensation policy, Ms. Ruddy receives $40,000 for her role as a director and an additional $4,500 for her role as a member of the nominating and corporate governance committee, each payable in quarterly installments, as well as reimbursement for reasonable travel expenses incurred by Ms. Ruddy for her attendance at meetings of our board of directors.

Joanne Viney

On December 18, 2024, we entered into a board of directors agreement with Joanne Viney (the “Viney Agreement”) pursuant to which Dr. Viney began serving as a director and the chair of the compensation

<div align='center'>24</div>

committee, effective as of January 6, 2025. Pursuant to the Viney Agreement, on February 6, 2025, the date on which the registration statement of our initial public offering was declared effective by the SEC, Dr. Viney received an initial equity grant under the non-employeedirector compensation policy. Following February 6, 2025, consistent with the terms of the non-employeedirector compensation policy, Dr. Viney receives $40,000 for her role as a director and an additional $12,000 for her role